Member Biography

Rachael R. Schulte, MD

Phone: (317) 948-5024
Phone: (317) 944-0920, Patient issues/appointments

575 Riley Hospital Drive
ROC 4340
Indianapolis, IN 46202
Fax: 317-944-3107

Faculty appointments

Assistant Professor of Clinical Pediatrics, Department of Pediatrics, IU School of Medicine
Affiliate member

I am a clinical-track faculty member with interests in clinical pharmacology and pharmacogenomics. My clinical areas of expertise are leukemia and vascular anomalies (the latter of which are not malignant but are being increasingly treated with targeted agents initially developed to treat cancer, such as alpelisib and trametinib, given similar abnormal growth pathways being involved as are seen in cancer). I am currently involved in clinical trials through Children's Oncology Group and upcoming trials through CaNVAS (Consortium of Investigators of Vascular Anomalies), a multi-institutional research consortium aiming to advance research into diagnosis and management of vascular anomalies, which are rare disorders of blood or lymphatic vessels that can cause significant morbidity and, in some cases, mortality if not managed optimally. As a heavily clinical faculty member to date, I have not been involved in the submission of cancer-related grants or the initiation of new clinical trials; however, I have had some leadership positions in these areas. I participate actively in the enrollment and treatment of patients on Children's Oncology Group research studies, on which most pediatric oncology patients in the country are treated. I have served as the site PI for 2 COG studies - a prior Phase 1 study in AML, and a current Phase 3 supportive care study (ACCL1931, levocarnitine for prevention of asparaginase-induced hepatotoxicity in acute lymphoblastic leukemia). I successfully applied for Riley to be a new site in the CaNVAS consortium in 2021, with me as the institutional PI, and I am actively participating in current retrospective studies through this consortium and in the near future there will be clinical trials of alpelisib and trametinib (and later, other agents) for vascular anomalies which will be open at Riley. I hope to be further involved in protocol creation and leadership in this group in the future. I am interested in pharmacokinetics and pharmacogenomics as they relate to the treatment of leukemia and vascular anomalies. During my fellowship, I received additional training in clinical pharmacology, as detailed on my CV. I currently have a collaboration with Emma Tillman, PharmD, from clinical pharmacology and hope to continue to grow this over time. I am interested in developing collaborations for translational research in vascular anomalies to better characterize their aberrant growth pathways and kinase activity/expression to improve drug therapy for these patients.